Shots:

• The MAA’s withdrawal is in response to the change in European product strategy for ABP 710. Additionally- Amgen will focus on the resources the most value for patients can be provided
• In Dec 2018- Amgen has also submitted BLA for ABP 710 to the US FDA and has two more biosimilars under development ABP 798 (rituximab- biosimilar) and ABP 959 (eculizumab- biosimilar)
• ABP 710 (100 mg powder) is a mAb anti-inflammatory drug targeted to treat rheumatoid arthritis- Crohn’s disease- ulcerative colitis- including ankylosing spondylitis- psoriatic arthritis- and psoriasis

Click here to read full press release/ article | Ref: EMA | Image: Twitter